Status:
WITHDRAWN
Pharmacology Study of Aerosolized Liposomal
Lead Sponsor:
University of New Mexico
Conditions:
Lung Diseases
Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
To determine the overall response rate to liposomal 9-Nitro-20 (S)-Camptothecin (L9NC) administered by aerosolization in patients with non-small-cell lung cancer (any stage). To determine toxicity pr...
Detailed Description
This is a single-arm, non-randomized Phase II trial of DLPC-9NC administered by aerosol 5 consecutive days per week for 8 weeks every 10 weeks. Dose: 0.4 mg/ml of 9-NC in aerosol reservoir for 60 min...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Patients participating in INST 1402C protocol
- Phase II Study of Aerosolized Liposomal-Nitro-20 (S)-Camptothecin (L9NC) in Patients with Advanced (NSCLC) Lung Cancer are eligible if their tumor is resectable with curative intent as determined by Dr. Reza Mehran.
Exclusion
Key Trial Info
Start Date :
April 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2007
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00250120
Start Date
April 1 2003
End Date
August 1 2007
Last Update
May 12 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of New Mexico
Albuquerque, New Mexico, United States, 87131